Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics

  • Farzam, Parisa
  • Johansson, Johannes D.
  • Mireles, Miguel
  • Jiménez Valerio, Gabriela
  • Martínez Lozano, Mar
  • Choe, Regine
  • Casanovas i Casanovas, Oriol
  • Durduran, Turgut
The longitudinal effect of an anti-vascular endothelial growth factor receptor 2 (VEGFR-2) antibody (DC 101) therapy on a xenografted renal cell carcinoma (RCC) mouse model was monitored using hybrid diffuse optics. Two groups of immunosuppressed male nude mice (seven treated, seven controls) were measured. Tumor microvascular blood flow, total hemoglobin concentration and blood oxygenation were investigated as potential biomarkers for the monitoring of the effect of therapy twice a week and were related to the final treatment outcome. These hemodynamic biomarkers have shown a clear differentiation between two groups by day four. Moreover, we have observed that pre-treatment values and early changes in hemodynamics are highly correlated with the therapeutic outcome demonstrating the potential of diffuse optics to predict the therapy response at an early time point. (C) 2017 Optical Society of America
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Resistance to antiangiogenic therapies by metabolic symbiosis in renal cell carcinoma PDX models and patients

  • Jiménez Valerio, Gabriela
  • Martínez Lozano, Mar
  • Bassani, Nicklas
  • Vidal-Bel, August
  • Ochoa de Olza, Maria
  • Suarez, Cristina
  • García del Muro Solans, Xavier
  • Carles, Joan
  • Viñals Canals, Francesc
  • Graupera i Garcia-Milà, Mariona
  • Indraccolo, Stefano
  • Casanovas i Casanovas, Oriol
Antiangiogenic drugs are used clinically for treatment of renal cell carcinoma (RCC) as a standard first-line treatment. Nevertheless, these agents primarily serve to stabilize disease, and resistance eventually develops concomitant with progression. Here, we implicate metabolic symbiosis between tumor cells distal and proximal to remaining vessels as a mechanism of resistance to antiangiogenic therapies in patient-derived RCC orthoxenograft (PDX) models and in clinical samples. This metabolic patterning is regulated by the mTOR pathway, and its inhibition effectively blocks metabolic symbiosis in PDX models. Clinically, patients treated with antiangiogenics consistently present with histologic signatures of metabolic symbiosis that are exacerbated in resistant tumors. Furthermore, the mTOR pathway is also associated in clinical samples, and its inhibition eliminates symbiotic patterning in patient samples. Overall, these data support a mechanism of resistance to antiangiogenics involving metabolic compartmentalization of tumor cells that can be inhibited by mTOR-targeted drugs.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Cancer: Limitations of therapies exposed

  • Casanovas i Casanovas, Oriol
Anti-angiogenic drugs, used for cancer treatment, target blood-vessel formation in tumours. Two studies commented here show that such drugs can reduce the efficiency of other anticancer agents and increase the aggressiveness of tumours.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Exploiting pleiotropic activities of semaphorins as multi-target therapies for cancer

  • Moserle, Lidia
  • Casanovas i Casanovas, Oriol
Semaphorins (SEMAs) are a superfamily of secreted or membrane‐associated glycoproteins implicated in the control of axonal wiring and involved in angiogenesis and cancer progression. Class‐3 SEMAs are the only secreted vertebrate SEMAs and several of them are regulated by protease‐mediated cleavage (Capparuccia & Tamagnone, 2009). Their high‐affinity receptors, Plexins and co‐receptor Neuropilins, are expressed in a wide variety of cell types including endothelial and tumour cells. Plexins show an intrinsic R‐Ras GAP activity, but interestingly also form complexes with additional transmembrane molecules, including certain receptor tyrosine kinases (RTKs) such as c‐Met, ErbB2 and vascular endothelial growth factor receptor 2 (VEGFR2), that are transactivated by Plexins and initiate critical signalling pathways. These functional interactions with transactivated kinase receptors are key to define the cellular activities of SEMAs and convert the SEMAs into pleiotropic molecules. Thus, SEMAs can positively or negatively modulate many intrinsic properties of tumour cells, such as proliferation, cell survival, alteration in cell adhesion and tumour invasiveness, but also modulate several stromal components including endothelial cell migration and survival (Capparuccia & Tamagnone, 2009; Serini et al, 2009)...
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Unraveling the Role of Angiogenesis in Cancer Ecosystems

  • Zuazo Gaztelu, Iratxe
  • Casanovas i Casanovas, Oriol
Activation of the tumor and stromal cell-driven angiogenic program is one of the first requirements in the tumor ecosystem for growth and dissemination. The understanding of the dynamic angiogenic tumor ecosystem has rapidly evolved over the last decades. Beginning with the canonical sprouting angiogenesis, followed by vasculogenesis and intussusception, and finishing with vasculogenic mimicry, the need for different neovascularization mechanisms is further explored. In addition, an overview of the orchestration of angiogenesis within the tumor ecosystem cellular and molecular components is provided. Clinical evidence has demonstrated the effectiveness of traditional vessel-directed antiangiogenics, stressing on the important role of angiogenesis in tumor establishment, dissemination, and growth. Particular focus is placed on the interaction between tumor cells and their surrounding ecosystem, which is now regarded as a promising target for the development of new antiangiogenics.
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics

  • Farzam, Parisa
  • Johansson, Johannes
  • Mireles, Miguel
  • Jiménez-Valerio, Gabriela
  • Martínez-Lozano, Mar
  • Choe, Regine
  • Casanovas, Oriol
  • Durduran, Turgut
The longitudinal effect of an anti-vascular endothelial growth factor receptor 2 (VEGFR-2) antibody (DC 101) therapy on a xenografted renal cell carcinoma (RCC) mouse model was monitored using hybrid diffuse optics. Two groups of immunosuppressed male nude mice (seven treated, seven controls) were measured. Tumor microvascular blood flow, total hemoglobin concentration and blood oxygenation were investigated as potential biomarkers for the monitoring of the effect of therapy twice a week and were related to the final treatment outcome. These hemodynamic biomarkers have shown a clear differentiation between two groups by day four. Moreover, we have observed that pre-treatment values and early changes in hemodynamics are highly correlated with the therapeutic outcome demonstrating the potential of diffuse optics to predict the therapy response at an early time point., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cancer: Limitations of therapies exposed

  • Casanovas i Casanovas, Oriol
Anti-angiogenic drugs, used for cancer treatment, target blood-vessel formation in tumours. Two studies commented here show that such drugs can reduce the efficiency of other anticancer agents and increase the aggressiveness of tumours.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Kidney cancer PDOXs reveal patient-specific pro-malignant effects of antiangiogenics and its molecular traits

  • Moserle, Lidia
  • Pons, Roser
  • Martínez-Lozano, Mar
  • Jiménez-Valerio, Gabriela A
  • Vidal, August
  • Suárez Rodríguez, Cristina
  • Trilla Herrera, Enric
  • Jiménez Flores, José Antonio
  • Torres Ramirez, Inés de
  • Carles Galceran, Joan
Antiangiogènica; Resistència al càncer; Inducció de metàstasi, Antiangiogénico; Resistencia al cáncer; Inducción de metástasis, Antiangiogenic; Cancer resistance; Induction of metastasis, An open debate in antiangiogenic therapies is about their consequence on tumor invasiveness and metastasis, which is undoubtedly relevant for patients currently treated with antiangiogenics, such as renal cell carcinoma patients. To address, this we developed an extensive series of 27 patient biopsy-derived orthotopic xenograft models (Ren-PDOX) that represent inter-patient heterogeneity. In specific tumors, antiangiogenics produced increased invasiveness and metastatic dissemination, while in others aggressiveness remained unchanged. Mechanistically, species-discriminative RNA sequencing identified a tumor cell-specific differential expression profile associated with tumor progression and aggressivity in TCGA RCC patients. Gene filtering using an invasion-annotated patient series pinpointed two candidate genes, of which ALDH1A3 differentiated the pro-invasive subtype of Ren-PDOXs. Validation in an independent series of 15 antiangiogenic-treated patients confirmed that pre-treatment ALDH1A3 can significantly discriminate patients with pro-aggressive response upon treatment. Overall, results confirm that effects of antiangiogenic drugs on tumor invasion and metastasis are heterogeneous and may profoundly affect the natural progression of tumors and promote malignancy. Furthermore, we identify a specific molecular biomarker that could be used to select patients that better benefit from treatment., This work was supported by research grants from ERC (ERC-StG-281830) EU-FP7, Ministerio de Ciencia, Innovación y Universidades, through the Retos Investigación grant, Refs: SAF2016-79347-R and PID2019-107557RB-I00/AEI/10.13039/501100011033, ISCIII Spain (AES, DTS17/00194), AGAUR-Generalitat de Catalunya (2017SGR771), Marató de TV3 (201910-30-31-32) and Italian Association for Cancer Research (AIRC) IG#14032, DOR - University of Padova, IOV 5x1000 fund. We thank CERCA Programme / Generalitat de Catalunya for institutional support.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Resistance to antiangiogenic therapies by metabolic symbiosis in renal cell carcinoma PDX models and patients

  • Jiménez Valerio, Gabriela
  • Martínez Lozano, Mar
  • Bassani, Nicklas
  • Vidal-Bel, August
  • Ochoa de Olza, Maria
  • Suarez, Cristina
  • García del Muro Solans, Xavier
  • Carles, Joan
  • Viñals Canals, Francesc
  • Graupera i Garcia-Milà, Mariona
  • Indraccolo, Stefano
  • Casanovas i Casanovas, Oriol
Antiangiogenic drugs are used clinically for treatment of renal cell carcinoma (RCC) as a standard first-line treatment. Nevertheless, these agents primarily serve to stabilize disease, and resistance eventually develops concomitant with progression. Here, we implicate metabolic symbiosis between tumor cells distal and proximal to remaining vessels as a mechanism of resistance to antiangiogenic therapies in patient-derived RCC orthoxenograft (PDX) models and in clinical samples. This metabolic patterning is regulated by the mTOR pathway, and its inhibition effectively blocks metabolic symbiosis in PDX models. Clinically, patients treated with antiangiogenics consistently present with histologic signatures of metabolic symbiosis that are exacerbated in resistant tumors. Furthermore, the mTOR pathway is also associated in clinical samples, and its inhibition eliminates symbiotic patterning in patient samples. Overall, these data support a mechanism of resistance to antiangiogenics involving metabolic compartmentalization of tumor cells that can be inhibited by mTOR-targeted drugs.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Unraveling the Role of Angiogenesis in Cancer Ecosystems

  • Zuazo Gaztelu, Iratxe
  • Casanovas i Casanovas, Oriol
Activation of the tumor and stromal cell-driven angiogenic program is one of the first requirements in the tumor ecosystem for growth and dissemination. The understanding of the dynamic angiogenic tumor ecosystem has rapidly evolved over the last decades. Beginning with the canonical sprouting angiogenesis, followed by vasculogenesis and intussusception, and finishing with vasculogenic mimicry, the need for different neovascularization mechanisms is further explored. In addition, an overview of the orchestration of angiogenesis within the tumor ecosystem cellular and molecular components is provided. Clinical evidence has demonstrated the effectiveness of traditional vessel-directed antiangiogenics, stressing on the important role of angiogenesis in tumor establishment, dissemination, and growth. Particular focus is placed on the interaction between tumor cells and their surrounding ecosystem, which is now regarded as a promising target for the development of new antiangiogenics.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Exploiting pleiotropic activities of semaphorins as multi-target therapies for cancer

  • Moserle, Lidia
  • Casanovas i Casanovas, Oriol
Semaphorins (SEMAs) are a superfamily of secreted or membrane‐associated glycoproteins implicated in the control of axonal wiring and involved in angiogenesis and cancer progression. Class‐3 SEMAs are the only secreted vertebrate SEMAs and several of them are regulated by protease‐mediated cleavage (Capparuccia & Tamagnone, 2009). Their high‐affinity receptors, Plexins and co‐receptor Neuropilins, are expressed in a wide variety of cell types including endothelial and tumour cells. Plexins show an intrinsic R‐Ras GAP activity, but interestingly also form complexes with additional transmembrane molecules, including certain receptor tyrosine kinases (RTKs) such as c‐Met, ErbB2 and vascular endothelial growth factor receptor 2 (VEGFR2), that are transactivated by Plexins and initiate critical signalling pathways. These functional interactions with transactivated kinase receptors are key to define the cellular activities of SEMAs and convert the SEMAs into pleiotropic molecules. Thus, SEMAs can positively or negatively modulate many intrinsic properties of tumour cells, such as proliferation, cell survival, alteration in cell adhesion and tumour invasiveness, but also modulate several stromal components including endothelial cell migration and survival (Capparuccia & Tamagnone, 2009; Serini et al, 2009)...
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics

  • Farzam, Parisa
  • Johansson, Johannes D.
  • Mireles, Miguel
  • Jiménez Valerio, Gabriela
  • Martínez Lozano, Mar
  • Choe, Regine
  • Casanovas i Casanovas, Oriol
  • Durduran, Turgut
The longitudinal effect of an anti-vascular endothelial growth factor receptor 2 (VEGFR-2) antibody (DC 101) therapy on a xenografted renal cell carcinoma (RCC) mouse model was monitored using hybrid diffuse optics. Two groups of immunosuppressed male nude mice (seven treated, seven controls) were measured. Tumor microvascular blood flow, total hemoglobin concentration and blood oxygenation were investigated as potential biomarkers for the monitoring of the effect of therapy twice a week and were related to the final treatment outcome. These hemodynamic biomarkers have shown a clear differentiation between two groups by day four. Moreover, we have observed that pre-treatment values and early changes in hemodynamics are highly correlated with the therapeutic outcome demonstrating the potential of diffuse optics to predict the therapy response at an early time point. (C) 2017 Optical Society of America
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics

  • Farzam, Parisa
  • Johansson, Johannes
  • Mireles, Miguel
  • Jiménez-Valerio, Gabriela
  • Martínez-Lozano, Mar
  • Choe, Regine
  • Casanovas, Oriol
  • Durduran, Turgut
The longitudinal effect of an anti-vascular endothelial growth factor receptor 2 (VEGFR-2) antibody (DC 101) therapy on a xenografted renal cell carcinoma (RCC) mouse model was monitored using hybrid diffuse optics. Two groups of immunosuppressed male nude mice (seven treated, seven controls) were measured. Tumor microvascular blood flow, total hemoglobin concentration and blood oxygenation were investigated as potential biomarkers for the monitoring of the effect of therapy twice a week and were related to the final treatment outcome. These hemodynamic biomarkers have shown a clear differentiation between two groups by day four. Moreover, we have observed that pre-treatment values and early changes in hemodynamics are highly correlated with the therapeutic outcome demonstrating the potential of diffuse optics to predict the therapy response at an early time point., Peer Reviewed, Postprint (published version)
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Kidney cancer PDOXs reveal patient-specific pro-malignant effects of antiangiogenics and its molecular traits

  • Moserle, Lidia
  • Pons, Roser
  • Martínez-Lozano, Mar
  • Jiménez-Valerio, Gabriela A
  • Vidal, August
  • Suárez Rodríguez, Cristina
  • Trilla Herrera, Enric
  • Jiménez Flores, José Antonio
  • Torres Ramirez, Inés de
  • Carles Galceran, Joan
Antiangiogènica; Resistència al càncer; Inducció de metàstasi, Antiangiogénico; Resistencia al cáncer; Inducción de metástasis, Antiangiogenic; Cancer resistance; Induction of metastasis, An open debate in antiangiogenic therapies is about their consequence on tumor invasiveness and metastasis, which is undoubtedly relevant for patients currently treated with antiangiogenics, such as renal cell carcinoma patients. To address, this we developed an extensive series of 27 patient biopsy-derived orthotopic xenograft models (Ren-PDOX) that represent inter-patient heterogeneity. In specific tumors, antiangiogenics produced increased invasiveness and metastatic dissemination, while in others aggressiveness remained unchanged. Mechanistically, species-discriminative RNA sequencing identified a tumor cell-specific differential expression profile associated with tumor progression and aggressivity in TCGA RCC patients. Gene filtering using an invasion-annotated patient series pinpointed two candidate genes, of which ALDH1A3 differentiated the pro-invasive subtype of Ren-PDOXs. Validation in an independent series of 15 antiangiogenic-treated patients confirmed that pre-treatment ALDH1A3 can significantly discriminate patients with pro-aggressive response upon treatment. Overall, results confirm that effects of antiangiogenic drugs on tumor invasion and metastasis are heterogeneous and may profoundly affect the natural progression of tumors and promote malignancy. Furthermore, we identify a specific molecular biomarker that could be used to select patients that better benefit from treatment., This work was supported by research grants from ERC (ERC-StG-281830) EU-FP7, Ministerio de Ciencia, Innovación y Universidades, through the Retos Investigación grant, Refs: SAF2016-79347-R and PID2019-107557RB-I00/AEI/10.13039/501100011033, ISCIII Spain (AES, DTS17/00194), AGAUR-Generalitat de Catalunya (2017SGR771), Marató de TV3 (201910-30-31-32) and Italian Association for Cancer Research (AIRC) IG#14032, DOR - University of Padova, IOV 5x1000 fund. We thank CERCA Programme / Generalitat de Catalunya for institutional support.